{"id":48246,"date":"2022-09-12T14:02:03","date_gmt":"2022-09-12T12:02:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\/"},"modified":"2022-09-12T14:02:03","modified_gmt":"2022-09-12T12:02:03","slug":"volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\/","title":{"rendered":"Volastra Therapeutics Named One of Fierce Biotech\u2019s \u201cFierce 15\u201d Companies of 2022"},"content":{"rendered":"
\n

NEW YORK–(BUSINESS WIRE)–Volastra Therapeutics<\/a>, an oncology company focused on exploiting chromosomal instability to treat cancer, today announced it has been named as one of Fierce Biotech\u2019s 2022 \u201cFierce 15,\u201d designating it as one of the most promising early-stage biotechnology companies in the industry.\n<\/p>\n

<\/a><\/p>\n

\n\u201cIt is an honor and tremendous validation of our team and progress to be among the Fierce 15,\u201d said Charles Hugh-Jones, M.D., FRCP, Chief Executive Officer at Volastra. \u201cOur unique understanding of chromosomal instability combined with our proprietary CINtech platform allows us to develop potentially life-saving therapies for patients. I am extremely proud of what we have accomplished in just the last three years, and the promise of what lies ahead.\u201d\n<\/p>\n

\nMichael Su, Ph.D., the company\u2019s Chief Scientific Officer, added, \u201cWe are particularly excited about our lead program, a KIF18A inhibitor that is on track to begin a Phase 1 trial in the second half of 2023. We recently announced compelling preclinical data<\/a> supporting the potential of Volastra\u2019s KIF18A inhibitor to induce tumor regression.\u201d\n<\/p>\n

\nNow in its 20th<\/sup> Fierce 15 selection, Fierce Biotech evaluates hundreds of early-stage companies from around the world for its annual list, which celebrates the spirit of being \u201cfierce\u201d\u2014 championing innovation and creativity in the face of strong competition. Winners are selected based on a variety of factors, such as the strength of their scientific approach, leadership, technology, partnerships, venture backers, and scale of unmet needs they are solving for.\n<\/p>\n

\nAbout Fierce Biotech<\/b>\n<\/p>\n

\nFierce Biotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news, and more. More than 450,000 top biopharma professionals rely on Fierce Biotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com<\/a>.\n<\/p>\n

\nAbout Volastra Therapeutics, Inc.<\/b>\n<\/p>\n

\nVolastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), a key vulnerability of cancer. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is rapidly developing and implementing new methods to exploit this vulnerability. Leveraging its proprietary CINtech platform, the company is advancing a novel synthetic lethal and immune-activating pipeline. Volastra\u2019s lead program targets KIF18A, a mitotic kinesin, with a first-in-human study anticipated to start in 2023. Volastra recently announced a multi-year, up to $1.1 billion drug discovery collaboration with Bristol Myers Squibb leveraging Volastra\u2019s proprietary CINtech platform to identify CIN-related targets. In addition, Volastra has a partnership with Microsoft to develop AI technologies for the high-throughput interrogation of CIN.\n<\/p>\n

\nFor more information, please visit volastratx.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia<\/b>
Lisa Qu
\n
LQu@tenbridgecommunications.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK–(BUSINESS WIRE)–Volastra Therapeutics, an oncology company focused on exploiting chromosomal instability to treat cancer, today announced it has been named as one of Fierce Biotech\u2019s 2022 \u201cFierce 15,\u201d designating it as one of the most promising early-stage biotechnology companies in the industry. \u201cIt is an honor and tremendous validation of our team and progress … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48246","6":"format-standard","7":"category-industry"},"yoast_head":"\nVolastra Therapeutics Named One of Fierce Biotech\u2019s \u201cFierce 15\u201d Companies of 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Volastra Therapeutics Named One of Fierce Biotech\u2019s \u201cFierce 15\u201d Companies of 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"NEW YORK–(BUSINESS WIRE)–Volastra Therapeutics, an oncology company focused on exploiting chromosomal instability to treat cancer, today announced it has been named as one of Fierce Biotech\u2019s 2022 \u201cFierce 15,\u201d designating it as one of the most promising early-stage biotechnology companies in the industry. \u201cIt is an honor and tremendous validation of our team and progress ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-12T12:02:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220912005130\/en\/1567280\/21\/FinalVolastraLogo2_RGB_Foundry._Sterling_Light_copy_%282%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Volastra Therapeutics Named One of Fierce Biotech\u2019s \u201cFierce 15\u201d Companies of 2022\",\"datePublished\":\"2022-09-12T12:02:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\\\/\"},\"wordCount\":473,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220912005130\\\/en\\\/1567280\\\/21\\\/FinalVolastraLogo2_RGB_Foundry._Sterling_Light_copy_%282%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\\\/\",\"name\":\"Volastra Therapeutics Named One of Fierce Biotech\u2019s \u201cFierce 15\u201d Companies of 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220912005130\\\/en\\\/1567280\\\/21\\\/FinalVolastraLogo2_RGB_Foundry._Sterling_Light_copy_%282%29.jpg\",\"datePublished\":\"2022-09-12T12:02:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220912005130\\\/en\\\/1567280\\\/21\\\/FinalVolastraLogo2_RGB_Foundry._Sterling_Light_copy_%282%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220912005130\\\/en\\\/1567280\\\/21\\\/FinalVolastraLogo2_RGB_Foundry._Sterling_Light_copy_%282%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Volastra Therapeutics Named One of Fierce Biotech\u2019s \u201cFierce 15\u201d Companies of 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Volastra Therapeutics Named One of Fierce Biotech\u2019s \u201cFierce 15\u201d Companies of 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\/","og_locale":"en_US","og_type":"article","og_title":"Volastra Therapeutics Named One of Fierce Biotech\u2019s \u201cFierce 15\u201d Companies of 2022 - Pharma Trend","og_description":"NEW YORK–(BUSINESS WIRE)–Volastra Therapeutics, an oncology company focused on exploiting chromosomal instability to treat cancer, today announced it has been named as one of Fierce Biotech\u2019s 2022 \u201cFierce 15,\u201d designating it as one of the most promising early-stage biotechnology companies in the industry. \u201cIt is an honor and tremendous validation of our team and progress ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-12T12:02:03+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220912005130\/en\/1567280\/21\/FinalVolastraLogo2_RGB_Foundry._Sterling_Light_copy_%282%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Volastra Therapeutics Named One of Fierce Biotech\u2019s \u201cFierce 15\u201d Companies of 2022","datePublished":"2022-09-12T12:02:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\/"},"wordCount":473,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220912005130\/en\/1567280\/21\/FinalVolastraLogo2_RGB_Foundry._Sterling_Light_copy_%282%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\/","url":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\/","name":"Volastra Therapeutics Named One of Fierce Biotech\u2019s \u201cFierce 15\u201d Companies of 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220912005130\/en\/1567280\/21\/FinalVolastraLogo2_RGB_Foundry._Sterling_Light_copy_%282%29.jpg","datePublished":"2022-09-12T12:02:03+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220912005130\/en\/1567280\/21\/FinalVolastraLogo2_RGB_Foundry._Sterling_Light_copy_%282%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220912005130\/en\/1567280\/21\/FinalVolastraLogo2_RGB_Foundry._Sterling_Light_copy_%282%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/volastra-therapeutics-named-one-of-fierce-biotechs-fierce-15-companies-of-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Volastra Therapeutics Named One of Fierce Biotech\u2019s \u201cFierce 15\u201d Companies of 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48246","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48246"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48246\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48246"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48246"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48246"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}